THE ROBOT●DAILY
Humanoid Robotics & Embodied AI News
← Latest briefingFunding & Market
Funding

Remedy Robotics Raises $62M to Push Its N1 Endovascular Robot Toward FDA Approval

The Robot Daily·2026-11-16·2 min read

Remedy Robotics has raised $62 million led by DCVC to advance N1, its AI-enabled robot for stroke and heart procedures, toward FDA approval.

Remedy Robotics has closed a $62 million Series B round to move its N1 endovascular robot toward clinical use, the San Francisco company said on Monday. DCVC led the round, and the money is earmarked for a pivotal clinical trial run with the University of California, work toward U.S. Food and Drug Administration approval for neurovascular procedures, and deployment of prototype N1 systems across the company's clinical partners.

New investors in the round include UC Investments, the University of California's investment office, Skip Capital and Hostplus, one of Australia's largest pension funds. Existing backers Build Collective, the fund started by Tony Fadell, Blackbird, Divergent Capital and KdT Ventures all increased their stakes.

N1 is an AI-enabled robotic platform built to carry out entire endovascular procedures, the catheter-based treatments used for stroke, heart attacks and other vascular emergencies. Its software uses machine learning to study preoperative imaging, rehearse a case in advance and align live 3D and 2D images during the procedure. The system is designed to work on site, remotely or autonomously, and Remedy says it completed the world's first remote neurointerventional procedures with N1 in October 2025.

The pitch is access. Endovascular treatment is the most effective option for many stroke and heart emergencies, but only a small number of hospitals have the specialists to deliver it. Remedy says 2.8 percent of eligible stroke patients worldwide receive endovascular treatment, and cites an annual economic burden of about $891 billion from stroke alone. The company works with more than 100 hospitals and is the exclusive robotics partner of SVIN Mission Thrombectomy, a global initiative to widen stroke treatment access.

The system is still in development and is not cleared for sale or clinical use in any country, so the trial and the FDA path are the gating steps. Remedy holds 48 patents covering the platform, including patents on machine learning applied to surgical robotics, and its clinical work has appeared in peer-reviewed journals including Interventional Neuroradiology and the American Journal of Neuroradiology.

Surgical robotics has drawn steady investor interest this year. Mosaic Intelligence Labs raised $47 million in seed funding earlier in November for surgical robots that navigate blood vessels. Remedy's round is larger and further along the clinical path, but both companies still have to prove their systems in trials before any revenue follows.

SourcesSource: Remedy Robotics (PR Newswire)